Core Laboratories Inc. (CLB)

From the record

Core Laboratories Inc.'s filings since 2023 show 1 warning event: a late-report notice (Form NT 10-K or NT 10-Q, the latest 2026-03-03) (its current reports).

From the record

Core Laboratories Inc.'s 5 filed years say what it did: revenue went from $470 million in fiscal 2021 to $527 million in fiscal 2025, up 2.9% a year; it rose in 4 of 4 years; it never fell from a peak; net income was positive in 5 of 5 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Core Laboratories Inc.'s diluted share count grew about 0.2% a year, and dividends and buybacks returned about 22% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 0 sales and 1 purchase of their own stock on the open market in the year to 2026-10-05, buying about $54 thousand (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Core Laboratories Inc. earned about 11 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 19 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 53 cents per dollar of assets, and net share issuance: its share count shrank 1.4% over the year (the filed statements).

From the record

Core Laboratories Inc.'s standing among 20 graded names in its industry family: revenue of $527 million in fiscal 2025 ranks in the bottom 25% by size; a net margin of 5.6% ranks in the top 32%; revenue growth of 2.4% a year over the last 3 filed years ranks in the bottom 48% (its annual reports).

From the record

Core Laboratories Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Bruno, Lawrence (Chairman and CEO, as filed), filing under that title since 2024-01-03, 2.9 years (bottom 23% of its family); most of the 11 officers and directors filing now have filed since the record of its people begins (2024-03-27), a floor of 2.6 years the record cannot see past, so that part is not read; 2 officer or director changes were reported on Form 8-K since 2023-11-13, against the 11 people in charge now (top 11%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Core Laboratories Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $23 million against debt of $113 million leaves -15.5% of its assets as net cash, bottom 39% of its family; cash from operations less capital spending is 4.9% of revenue (top 37%); a gross margin of 20.7% (top 50%) (its annual report).

From the record

Core Laboratories Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 2.4% a year over the last three filed years against 2.9% over all 5, slowing (top 42% of its family); the newest year grew 0.5% (top 47%); capital spending grew 3.1% a year (bottom 38%) (its annual reports). Core Laboratories Inc. reported 2 product lines in fiscal 2025: Service at $399 million (76%), Product at $127 million (24%); 1 of 2 grew against the year before (its annual report).

From the record

Core Laboratories Inc.'s newest year against its own record: revenue of $527 million in fiscal 2025 came in 2.8% below the $542 million its prior three years' pace pointed to (top 31% of its family); net income of $30 million against a prior three-year average of $29 million (top 42%); a net margin of 5.6% against 5.7% before (top 42%) (its annual reports).